Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
212Pb-NG001 in mCRPC
NCT05725070Phase 1Completed
- Sponsor
- ARTBIO
- Start
- Mar 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AB001 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by ARTBIO. Primary endpoint: Feasibility of SPECT/CT gamma camera imaging for uptake of 212Pb-NG001 up to 28 days. Started Mar 2023; status: completed.
02
Drugs
AB001
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05725070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05725070.